2. Inovelon(R) (rufinamide) SPC - Inovelon Tablets and Oral Suspension. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... Accessed November 2016
3. Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs (NCT01405053). Available at: https://clinicaltrials.gov/ct2/show/reco... November 2016
4. Tyagi S, et al. Pharmacological management of Lennox-Gastaut Syndrome-a difficult-to-treat form of childhood-onset epilepsy: an overview. International Journal of Pharma and Bio Sciences. 2010:1(3). Available at: http://www.ijpbs.net/issue-3/82.pdf . Accessed August 2016
5. Wier H et al. Rufinamide for Pediatric Patients with Lennox-Gastaut Syndrome. Pediatric Drugs 2011;13(2):97-106
6. Xu M et al. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects. European Journal of Drug Metabolism and Pharmacokinetics 2016;41(5):541-548
7. Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe. http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510... June 2016)
December 2016
Inovelon-EU0029
CONTACT: Media Enquiries: Eisai, Cressida Robson / Ben Speller,+44-7908-314-155 / +44-7908-409-416, Cressida_Robson@eisai.net /Ben_Speller@eisai.net; Tonic Life Communications, Alex Davies / StanJackson, +44-7896-954-865 / +44-7747-718-279, Alex.Davies@toniclc.com /Stan.Jackson@toniclc.com